{"prompt": "['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 48 of 51', 'Study ID RCB: 2020-A00652-37', '13 References', 'Augustin, M., Gajur, A.I., Reich, C., Rustenbach, S.J., and Schaefer, I. (2008). Benefit', 'Evaluation in Vitiligo Treatment: Development and Validation of a Patient-Defined Outcome', 'Questionnaire. Dermatology 217, 101-106.', 'Battisti, W.P., Wager, E., Baltzer, L., Bridges, D., Cairns, A., Carswell, C.I., Citrome, L., Gurr, J.A.,', 'Mooney, L.A., Moore, B.J., et al. (2015). Good Publication Practice for Communicating', 'Company-Sponsored Medical Research: GPP3Good Publication Practice for Company-', 'Sponsored Research (GPP3). Annals of Internal Medicine 163, 461-464.', 'Berger, M.L., Mamdani, M., Atkins, D., and Johnson, M.L. (2009). Good Research Practices for', 'Comparative Effectiveness Research: Defining, Reporting and Interpreting Nonrandomized', 'Studies of Treatment Effects Using Secondary Data Sources: The ISPOR Good Research', 'Practices for Retrospective Database Analysis Task Force Report-Part I. Value in Health 12,', '1044-1052.', 'Cardiff University (2019). Dermatology Life Quality Index.', \"Chassany, O. (2003). De la maladie chronique a la qualit\u00e9 de vie M\u00e9thodes d' '\u00e9valuation.\", 'Revue Des Maladies Respiratoires 20, 34-37.', 'Daud\u00e9n, E., Puig, L., Ferr\u00e1ndiz, C., S\u00e1nchez-Carazo, J.L., Hernanz-Hermosa, J.M., and the', 'Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology (2016).', 'Consensus document on the evaluation and treatment of moderate-to-severe psoriasis:', 'Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Journal of the', 'European Academy of Dermatology and Venereology 30, 1-18.', 'von Elm, E., Altman, D.G., Egger, M., Pocock, S.J., G\u00f8tzsche, P.C., and Vandenbroucke, J.P.', '(2007). The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)', 'statement: guidelines for reporting observational studies. The Lancet 370, 1453-1457.', 'European Commission (2001). Directive 2001/20/EC of 4 April 2001 on the approximation of', 'the laws, regulations and administrative provisions of the Member States relating to the', 'implementation of good clinical practice in the conduct of clinical trials on medicinal', 'products for human use, 2001.', 'European Commission (2016). Regulation6/679 of the European Parliament and the Council', 'of the European Union 27 April 2016 on the protection of natural persons with regard to the', 'processing of personal data and on the free movement of such data, and repealing Directive', '95/46/EC (General Data Protection Regulation).', 'European Medicines Agency (2010). The European Network of Centres for', 'Pharmacoepidemiology and Pharmacovigilance (ENCePP) Guide on Methodological', 'Standards in Pharmacoepidemiology (Revision 5).', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 49 of 51', 'Study ID RCB: 2020-A00652-37', 'European Medicines Agency (2017). Guideline on good pharmacovigilance practices (GVP)', 'Module VI - Collection, management and submission of reports of suspected adverse', 'reactions to medicinal products (Rev 2).', 'Feuerhahn, J., Blome, C., Radtke, M., and Augustin, M. (2012). Validation of the patient', 'benefit index for the assessment of patient-relevant benefit in the treatment of psoriasis.', 'Archives of Dermatological Research 304, 433-441.', 'Finlay, A.Y., and Khan, G.K. (1994). Dermatology Life Quality Index (DLQI) - a simple practical', 'measure for routine clinical use. Clinical and Experimental Dermatology 19, 210-216.', 'Food and Drug Administration (2013). Guidance for Industry and FDA Staff. Best Practices for', 'Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic', 'Healthcare Data.', 'Forestier, B., Anthoine, E., Reguiai, Z., Fohrer, C., and Blanchin, M. (2019). A systematic', 'review of dimensions evaluating patient experience in chronic illness. Health and Quality of', 'Life Outcomes 17, 19-19.', 'Gelfand, J.M., Weinstein, R., Porter, S.B., Neimann, A.L., Berlin, J.A., and Margolis, D.J. (2005).', 'Prevalence and Treatment of Psoriasis in the United Kingdom: A Population-Based Study.', 'Archives of Dermatology 141, 1537-1541.', 'Huerta, C., Rivero, E., and Rodr\u00edguez, L.A.G. (2007). Incidence and Risk Factors for Psoriasis in', 'the General Population. Archives of Dermatology 143, 1559-1565.', 'Ippagunta, S.K., Gangwar, R., Finkelstein, D., Vogel, P., Pelletier, S., Gingras, S., Redecke, V.,', 'and H\u00e4cker, H. (2016). Keratinocytes contribute intrinsically to psoriasis upon loss of Tnip1', 'function. Proceedings of the National Academy of Sciences of the United States of America', '113, E6162-E6171.', 'Kerdel, F., and Zaiac, M. (2015). An evolution in switching therapy for psoriasis patients who', 'fail to meet treatment goals. Dermatologic Therapy 28, 390-403.', 'van de Kerkhof, P.C.M., Reich, K., Kavanaugh, A., Bachelez, H., Barker, J., Girolomoni, G.,', 'Langley, R.G., Paul, C.F., Puig, L., and Lebwohl, M.G. (2015). Physician perspectives in the', 'management of psoriasis and psoriatic arthritis: results from the population-based', 'Multinational Assessment of Psoriasis and Psoriatic Arthritis survey. Journal of the European', 'Academy of Dermatology and Venereology : JEADV 29, 2002-2010.', 'Krueger, G., Koo, J., Lebwohl, M., Menter, A., Stern, R.S., and Rolstad, T. (2001). The Impact of', 'Psoriasis on Quality of Life: Results of a 1998 National Psoriasis Foundation Patient-', 'Membership Survey. Archives of Dermatology 137, 280-284.', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']\n\n###\n\n", "completion": "END"}